Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of XC221 (Aterixen) in Uncomplicated Influenza or ARVI
NCT03830905Phase 2Completed
- Sponsor
- PHARMENTERPRISES LLC
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aterixen in influenza and acute respiratory viral infection (ARVI), sponsored by PHARMENTERPRISES LLC. Primary endpoint: Time to sustained improvement in clinical symptoms according to the Modified Jackson Scale at Day 14. Started Jan 2019; status: completed.
02
Drugs
aterixen
03
Conditions
influenzaacute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT03830905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830905.